Posttransplant autoimmune encephalitis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 7, 2018
- Accepted in final form June 22, 2018
- First Published August 20, 2018.
Author Disclosures
- Devon A. Cohen, MD,
- A. Sebastian Lopez-Chiriboga, MD,
- Sean J. Pittock, MD,
- Avi Gadoth, MD,
- Anastasia Zekeridou, MD,
- Barry A. Boilson, MD,
- William J. Hogan, MB, BCh,
- John J. Poterucha, MD,
- Katelynn M. Wilton,
- Yi Lin, MD, PhD and
- Eoin P. Flanagan, MD
- Devon A. Cohen, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- A. Sebastian Lopez-Chiriboga, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sean J. Pittock, MD,
NONE
NONE
NONE
NONE
Dr. Pittock and Mayo Clinic have a financial interest in patents (#12/678,350 filed 2010 and #12/573,942 filed 2008) that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker. Dr Pittock has a patent pending for GFAP, Septin-5 and MAP1B autoantibodies as biomarkers of neurological autoimmunity.
NONE
NONE
Dr. Pittock has provided consultation to Alexion Pharmaceuticals and Medimmune but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.
NONE
NONE
NONE
Dr Pittock has received research funding from Grifols, Medimmune, Alexion and AEA (Autoimmune Encephalitis Associations).
RO1 NS065829-01
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Avi Gadoth, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anastasia Zekeridou, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Barry A. Boilson, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- William J. Hogan, MB, BCh,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Osiris therapeutics, clinical trial support only (graft versus host disease, unrelated to current study), no personal reimbursement.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John J. Poterucha, MD,
NONE
NONE
NONE
American Journal of Gastroenterology, ed advisory board, many years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katelynn M. Wilton,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
KMW was supported by a training grant from the National Institutes of General Medical Sciences (grant T32-GM-65841)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yi Lin, MD, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eoin P. Flanagan, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am currently a site primary investigator in a randomized clinical trial on Medi551 in neuromyelitis optica spectrum disorder run by Medimmune. I receive compensation for time related to that activity.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (D.A.C., A.S.L-C., S.J.P., A.G., A.Z., E.P.F.), Department of Laboratory Medicine and Pathology (S.J.P., E.P.F.), Department of Medicine, Divisions of Cardiology (B.A.B.), Department of Hematology (W.J.H., Y.L.), Department of Gastroenterology (J.J.P.), and Mayo Medical School (K.M.W.), Mayo Clinic, Rochester, MN.
- Correspondence
Dr. Flanagan flanagan.eoin{at}mayo.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsyRyo Ogawa, Ichiro Nakashima, Toshiyuki Takahashi et al.Neurology: Neuroimmunology & Neuroinflammation, January 16, 2017 -
Article
Clinical and imaging features of children with autoimmune encephalitis and MOG antibodiesAndreas Wegener-Panzer, Robert Cleaveland, Eva-Maria Wendel et al.Neurology: Neuroimmunology & Neuroinflammation, May 01, 2020 -
Article
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritisSudarshini Ramanathan, Stephen W. Reddel, Andrew Henderson et al.Neurology - Neuroimmunology Neuroinflammation, October 29, 2014 -
Article
Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeletonRussell C. Dale, Esther M. Tantsis, Vera Merheb et al.Neurology - Neuroimmunology Neuroinflammation, May 22, 2014